Xu R, You T, Liu C, Lin Q, Guo Q, Zhong G
Front Oncol. 2023; 13:1216446.
PMID: 37583930
PMC: 10424446.
DOI: 10.3389/fonc.2023.1216446.
Andrade de Oliveira K, Sengupta S, Yadav A, Clarke R
Front Endocrinol (Lausanne). 2023; 14:1083048.
PMID: 36909339
PMC: 9997040.
DOI: 10.3389/fendo.2023.1083048.
Kavan S, Kruse T, Vogsen M, Hildebrandt M, Thomassen M
Cancer Metastasis Rev. 2022; 41(2):433-446.
PMID: 35286542
DOI: 10.1007/s10555-022-10023-9.
Inda M, van Swinderen P, van Brussel A, Moelans C, Verhaegh W, van Zon H
Cancers (Basel). 2021; 13(6).
PMID: 33809754
PMC: 8002348.
DOI: 10.3390/cancers13061345.
Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G
Cells. 2020; 9(12).
PMID: 33316954
PMC: 7764472.
DOI: 10.3390/cells9122644.
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
Baliu-Pique M, Pandiella A, Ocana A
Cancers (Basel). 2020; 12(11).
PMID: 33167363
PMC: 7694303.
DOI: 10.3390/cancers12113271.
Tumor Pre-Analytics in Molecular Pathology: Impact on Protein Expression and Analysis.
Neumeister V, Juhl H
Curr Pathobiol Rep. 2019; 6(4):265-274.
PMID: 30595971
PMC: 6290693.
DOI: 10.1007/s40139-018-0179-5.
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
Saha A, Harowicz M, Cain E, Hall A, Hwang E, Marks J
Breast Cancer Res Treat. 2018; 172(1):123-132.
PMID: 29992418
PMC: 6588400.
DOI: 10.1007/s10549-018-4879-7.
Tumor Heterogeneity in Breast Cancer.
Turashvili G, Brogi E
Front Med (Lausanne). 2017; 4:227.
PMID: 29276709
PMC: 5727049.
DOI: 10.3389/fmed.2017.00227.
Oncolytic viruses: emerging options for the treatment of breast cancer.
Suryawanshi Y, Zhang T, Essani K
Med Oncol. 2017; 34(3):43.
PMID: 28185165
DOI: 10.1007/s12032-017-0899-0.
Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis.
Ellsworth R, Toro A, Blackburn H, Decewicz A, Deyarmin B, Mamula K
Cancer Growth Metastasis. 2015; 8:15-24.
PMID: 26279627
PMC: 4511091.
DOI: 10.4137/CGM.S29490.
Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes.
Shriver C, Hueman M, Ellsworth R
J Exp Clin Cancer Res. 2015; 33:116.
PMID: 25551369
PMC: 4322560.
DOI: 10.1186/s13046-014-0116-3.
Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.
Vassilakopoulou M, Parisi F, Siddiqui S, England A, Zarella E, Anagnostou V
Lab Invest. 2014; 95(3):334-41.
PMID: 25418580
DOI: 10.1038/labinvest.2014.139.
Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.
Tsai Y, Hsu H, Chen C, Hsu K, Fan H, Chang H
Ir J Med Sci. 2013; 183(1):71-5.
PMID: 23757214
DOI: 10.1007/s11845-013-0975-1.
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.
Neumeister V, Anagnostou V, Siddiqui S, England A, Zarrella E, Vassilakopoulou M
J Natl Cancer Inst. 2012; 104(23):1815-24.
PMID: 23090068
PMC: 3514166.
DOI: 10.1093/jnci/djs438.
Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma.
Douglas-Jones A, Collett N, Morgan J, Jasani B
J Clin Pathol. 2001; 54(12):951-5.
PMID: 11729216
PMC: 1731334.
DOI: 10.1136/jcp.54.12.951.
Oestrogen receptor: a stable phenotype in breast cancer.
Robertson J
Br J Cancer. 1996; 73(1):5-12.
PMID: 8554983
PMC: 2074280.
DOI: 10.1038/bjc.1996.2.
Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer.
Lluch A, Anton A, Carbonell F, Alberola V
Breast Cancer Res Treat. 1987; 9(1):69-70.
PMID: 3593992
DOI: 10.1007/BF01806696.
Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.
Scheres H, de Goeij A, Rousch M, Hondius G, Willebrand D, GIJZEN A
J Clin Pathol. 1988; 41(6):623-32.
PMID: 3384997
PMC: 1141542.
DOI: 10.1136/jcp.41.6.623.
Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.
Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M
Breast Cancer Res Treat. 1985; 5(3):269-76.
PMID: 2992647
DOI: 10.1007/BF01806021.